Teva announces fda approval of austedo® xr (deutetrabenazine) extended-release tablets, a new once-daily formulation of austedo® (deutetrabenazine) tablets

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced that the u.s. food and drug administration (fda) has approved austedo xr (deutetrabenazine) extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia (td) and chorea associated with huntington's disease (hd). austedo xr is an additional formulation of the currently marketed twice-daily austedo.
TEVA Ratings Summary
TEVA Quant Ranking